Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02046213 · ClinicalTrials.gov registry record · Phase 1

An Open-label, Single-dose Study to Determine the Metabolism and Excretion of [14C]E2006 in Healthy Male Subjects

A Phase 1 study, sponsored by Eisai.

Completed
Registry status
Phase 1
Development phase
16
Enrollment target

NCT02046213: Completed Phase 1 study, sponsored by Eisai.

NCT02046213 is a Phase 1 study that has completed, run by Eisai. The registered enrollment target is 16 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (73% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02046213, a Phase 1 study, has completed, sponsored by Eisai.

COMPLETED
Registry status
Phase 1
Development phase
16 participants
Enrollment target

Study Summary

The purpose of this study is to determine the metabolism and excretion of \[14C\]E2006 in healthy male subjects.

Primary Outcome

Total radioactivity derived from \[14C\]E2006-related material and E2006 will be analyzed in urine and feces. \[14C\]E2006 radiolabeled material will be quantified in urine and feces for total radioactivity using a scintillation counting method and/or an accelerator mass spectrometry.

Interventions

  • DRUG E2006

Trial Details

FieldValue
Enrollment Target 16 participants
Start Date 2014-02
Est. Completion 2014-05
Phase Phase 1
Eisai

287 total trials

What the finished NCT02046213 record still lists

NCT02046213 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (73% lower).

The record links to 0 conditions, and to 1 intervention - of which E2006 is the first listed.

NCT02046213 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02046213 about?

NCT02046213 is a clinical study titled "An Open-label, Single-dose Study to Determine the Metabolism and Excretion of [14C]E2006 in Healthy Male Subjects". The purpose of this study is to determine the metabolism and excretion of \[14C\]E2006 in healthy male subjects.

What is the current status of trial NCT02046213?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2014-02. Estimated completion is 2014-05.

What interventions are being tested in trial NCT02046213?

The interventions under investigation include: E2006 (DRUG).

Who is sponsoring clinical trial NCT02046213?

This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02046213's enrollment target sits among peer trials

16 1786th of 2000 higher than 203 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02422641 · 16 participants · Phase 2

    Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis

  • NCT02851758 · 16 participants · NA

    Transplantation of Autologously Derived Mitochondria Following Ischemia

  • NCT03291028 · 16 participants

    Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma

  • NCT03425526 · 16 participants · Phase 1

    Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02046213, the US trial registry maintained by the National Library of Medicine. NCT02046213 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.